SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%
新闻
PCRX
--
0.00%
--
Benzinga's Top Upgrades, Downgrades For May 27, 2020
Upgrades
Benzinga · 4天前
Pacira BioSciences to Present at the 2020 Jefferies Virtual Healthcare Conference
GlobeNewswire · 4天前
Guggenheim Initiates Coverage On Pacira BioSciences with Neutral Rating
Guggenheim analyst Dana Flanders initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Neutral rating.
Benzinga · 4天前
J.P. Morgan picks spec pharma favorites after earnings
News is free at Seeking Alpha. This post is a Notable Call. Notable Calls are a Premium feature. To access this and other Notable Calls, try a free trial t
seekingalpha · 05/20 01:07
Sandell buys Taubman, exits Pacira BioSciences
Sandell Asset Management adds Taubman Centers (TCO -0.2%) to its portfolio, acquiring 425K shares, and almost doubles its holdings in Advanced Disposal Ser
seekingalpha · 05/15 19:36
Pacira BioSciences to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
GlobeNewswire · 05/13 12:30
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/11 09:07
Pacira BioSciences, Inc. (PCRX) Q1 2020 Earnings Call Transcript
MotleyFool.com · 05/08 23:30
Stifel Maintains Hold on Pacira BioSciences, Lowers Price Target to $48
Stifel maintains Pacira BioSciences (NASDAQ:PCRX) with a Hold and lowers the price target from $49 to $48.
Benzinga · 05/08 17:41
SVB Leerink Maintains Outperform on Pacira BioSciences, Raises Price Target to $45
SVB Leerink maintains Pacira BioSciences (NASDAQ:PCRX) with a Outperform and raises the price target from $44 to $45.
Benzinga · 05/08 10:31
Pacira BioSciences EPS beats by $0.23, beats on revenue
Pacira BioSciences (NASDAQ:PCRX): Q1 Non-GAAP EPS of $0.53 beats by $0.23; GAAP EPS of $0.19 beats by $0.10. Revenue of $105.68M (+15.7% Y/Y) beats by $4.0
seekingalpha · 05/07 17:05
Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update
GlobeNewswire · 05/07 13:00
Pacira BioSciences Q1 EPS $0.530 Beats $0.320 Estimate, Sales $105.684M Beat $102.970M Estimate
Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.530 per share which beat the analyst consensus estimate of $0.320 by 65.63 percent. This is a 140.91 percent increase over earnings of $0.220 per share
Benzinga · 05/07 12:27
Pacira BioSciences Q1 EPS $0.530 Beats $0.320 Estimate, Sales $105.700M Beat $102.970M Estimate
Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.530 per share which beat the analyst consensus estimate of $0.320 by 65.63 percent. This is a 140.91 percent increase over earnings of $0.220 per share
Benzinga · 05/07 12:05
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.)
Benzinga · 05/07 11:42
Pacira Pharmaceuticals Q1 2020 Earnings Preview
Seeking Alpha - Article · 05/06 16:45
Pacira BioSciences Appoints Donald C. Manning, M.D., Ph.D. as Chief Medical Officer
GlobeNewswire · 05/04 12:30
Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020
GlobeNewswire · 04/30 12:30
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $52
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $56 to $52.
Benzinga · 04/30 10:42
Why Pacira BioSciences, Inc.'s (NASDAQ:PCRX) CEO Pay Matters To You
Simply Wall St. · 04/23 13:59